Synthesis of 1,5-diarylpyrazol-3-propanoic acids towards inhibition of cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4 formation

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 8, 2010, Pages 497-505

  Ergün, Burcu Çalişkan ^a   Nuñez, Maria Teresa ^b   Labeaga, Luis ^b   Ledo, Francisco ^b   Darlington, Janice ^c   Bain, Gretchen ^c   Çakir, Bilge ^a   Banoglu, Erden ^a  

^a GAZI UNIVERSITY   (Turkey)

^b Faes Farma SA   (Spain)

^c Amira Pharmaceuticals   (United States)

Author keywords

Aryl propanoic acids; COX 1 2 inhibitors; Leukotriene B4; Pyrazole

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; LEUKOTRIENE B4; PROPIONIC ACID DERIVATIVE; ROFECOXIB; CYCLOOXYGENASE 2; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; NEUTROPHIL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; INFRARED SPECTROPHOTOMETRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ARACHIDONATE 5-LIPOXYGENASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; INDICATORS AND REAGENTS; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; NEUTROPHILS; PROPIONATES; PYRAZOLES; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956371766     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296318     Document Type: Article

References (32)

1. Coussens LM, Werb Z. Inflammation and cancer . Nature. 2002;420:860-7.
2. Nathan C. Points of control in inflammation. Nature. 2002; 420:846-52.
3. Mehrabian M, Allayee H. 5-Lipoxygenase and atherosclerosis. Curr Opin Lipidol. 2003;14:447-57.
4. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220:568-75. (Pubitemid 13130140)
5. Weissmann G. Prostaglandins as modulators rather than mediators of inflammation. J Lipid Mediat. 1993;6:275-86. (Pubitemid 23152460)
6. Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer . Mol Cancer. 2003; 2:10. (Pubitemid 38751487)
7. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy . Faseb J. 2003; 17:1986-95. (Pubitemid 37392443)
8. Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther. 2006;112:701-18.
9. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease . Nat Rev Drug Discov. 2005;4: 664-72.
10. Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs . Eur J Med Chem. 2003;38:645-59. (Pubitemid 36980661)
11. Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C, et al. Celecoxib inhibits 5-lipoxygenase . Biochem Pharmacol. 2008;76:862-72.
12. Chintakunta VK, Akella V, Vedula MS, Mamnoor PK, Mishra P, Casturi SR, et al. 3-O-substituted benzyl pyridazinone derivatives as COX inhibitors. Eur J Med Chem. 2002;37:339-47.
13. Biancalani C, Giovannoni MP, Pieretti S, Cesari N, Graziano A, Vergelli C, et al. Further studies on arylpiperazinyl alkyl pyridazinones: discovery of an exceptionally potent, orally active, antinociceptive agent in thermally induced pain. J Med Chem. 2009;52:7397-409.
14. Giovannoni MP, Cesari N, Vergelli C, Graziano A, Biancalani C, Biagini P, et al. 4-amino-5-substituted-3(2H)-pyridazinones as orally active antinociceptive agents: synthesis and studies on the mechanism of action. J Med Chem. 2007;50:3945-53.
15. Banoglu E, Okcelik B, Kupeli E, Unlu S, Yesilada E, Amat M, et al. Amide derivatives of [5-chloro-6-(2-chloro/fluorobenzoyl)- 2-benzoxazolinone-3-yl] acetic acids as potential analgesic and anti-inflammatory compounds . Arch Pharm (Weinheim). 2003;336:251-7.
16. Banoglu E, Akoglu C, Unlu S, Kupeli E, Yesilada E, Sahin MF. Amide derivatives of [6-(5-methyl-3-phenylpyrazole- 1-yl)-3(2H)-pyridazinone-2-yl] acetic acids as potential analgesic and anti-inflammatory compounds . Arch Pharm (Weinheim). 2004;337:7-14.
17. Banoglu E, Akoglu C, Unlu S, Ergun BC, Kupeli E, Yesilada E, et al. Synthesis of amide derivatives of [6-(3,5-dimethylpyrazol- 1-yl)-3(2H)- pyridazinone-2-yl] acetic acid and their analgesic and anti-inflammatory properties . Arzneimittelforschung. 2005;55(9):520-7.
18. Banoglu E, Sukuroglu M, Çalişkan Ergün B, Nacak Baytas S, Aypar E, Ark M. Synthesis of the amide derivatives of 3-[1-(3-pyridazinyl)- 5-phenyl-1H-pyrazole-3-yl]propanoic acids as potential analgesic compounds . Turkish J Chem. 2007;31:677-87.
19. Unlu S, Banoglu E, Ito S, Niiya T, Eren G, Okcelik B, et al. Synthesis, characterization and preliminary screening of regioisomeric 1-(3-pyridazinyl)-3- arylpyrazole and 1-(3- pyridazinyl)-5-arylpyrazole derivatives towards cyclooxygenase inhibition. J Enzyme Inhib Med Chem. 2007;22: 351-61.
20. Druey J, Meier K, Eichenberger K. Chemotherapeutic studies in the heterocyclic series. IV. Pyridazines. 1. Cyclic maleic and citraconic hydrazides . Helv Chim. Acta. 1954; 37:121-33.
21. Abdel-magid AF, Harris BD, Maryanoff CA. Process for preparing 1,5-diaryl-3-substituted pyrazoles . US 6384233. 2002.
22. Murray W, Watcher MP. Synthesis and properties of aryl-1,3-dioxo carboxylic acids . J Org Chem. 1990;55:3424-26.
23. Murray W, Wachter MP. Regioselective synthesis of 1,5-disubstituted pyrazoles . EP0293221. 1988.
24. Murray W, Lalan P, Connolly PJ. The mechanism of formation of 6-aryl-4,6-dioxohexanoic acids from aryl ketones and succinic acids . Tetrahedron Lett. 1993;34:5189-92.
25. Wachter MP, Ferro MP. Pharmacologically active 1,5-diaryl- 3-substitutedpyrazoles and method for synthesizing the same. EP0248594. 1987.
26. Wachter MP, Murray WV. Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same. US 5242940 . 1993.
27. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro . Prostaglandins. 1994;47:55-9. (Pubitemid 24053843)
28. Janusz JM, Young PA, Ridgeway JM, Scherz MW, Enzweiler K, Wu LI, et al. New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7- tert-Buty1-2,3-dihydro-3, 3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituent . J Med Chem. 1998;41:1112-23.
29. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes . Nature. 1980;286:264-65.
30. Murray W, Wachter M, Barton D, Forero-Kelly Y. The regio-selective synthesis of tepoxalin, 3-[5-(4-chlorophenyl)-1-(4-metoxyphenyl)-3-pyrazolyl]-N- hydroxy-N-methylpropanamide and related 1,5-diarylpyrazole anti-inflammatory agents. Synthesis. 1991:18-20.
31. Singh SK, Srinivasa Reddy M, Shivaramakrishna S, Kavitha D, Vasudev R, Moses Babu J, et al. Modified reaction conditions to achieve high regioselectivity in the two component synthesis of 1,5-diarylpyrazoles . Tetrahedron Lett. 2004;45:7679-82. (Pubitemid 39243350)
32. Dannhardt G, Laufer S. Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? Curr Med Chem. 2000;7:1101-12.